{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:15:17Z","timestamp":1767942917523,"version":"3.49.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3M2141, CFRPG3L0031"],"award-info":[{"award-number":["CMRPG3M2141, CFRPG3L0031"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid hormone replacement therapy is widely used to treat hypothyroidism, but there is limited research on its effects in patients with diabetes mellitus (DM). Some studies indicate that this therapy might improve lipid profiles in DM patients, but even with normalized TSH levels from thyroxine replacement, LDL and total cholesterol levels remain higher than in people with normal thyroid function. Additionally, the effect of this therapy on major adverse cardiovascular events (MACE) in DM patients is still uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This retrospective study investigated the occurrence of major adverse cardiovascular events (MACE) in participants receiving thyroxine with diabetes and compared the risk factors between the MACE and non-MACE groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used longitudinal claims data from 2008 to 2017 from the Chang Gung Research Database. Individuals with diabetes who used thyroxine were included. The primary outcome was the occurrence of MACE. The secondary outcomes were the differences between the two groups (MACE vs. no MACE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 1:1 group matching by propensity score between MACE and non-MACE groups by sex, age, and interval of using thyroxine, there were 416 patients in each group. Patients with worse renal function (eGFR &amp;lt;45 ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ), hypertension, history of diabetic microvascular complications, end-stage renal disease (ESRD), coronary heart disease (CHD), heart failure, cerebrovascular accident (CVA), and diabetic foot infection had a higher risk of experiencing MACE. Free T4 had a weak positive correlation with HDL, and TSH had a weak positive correlation with LDL and a negative correlation with HDL (correlation coefficient,\n                      <jats:italic>p<\/jats:italic>\n                      -value: 0.131, 0.022; 0.124, 0.016; and -0.157, 0.003, respectively). There were no optimal cutoff points according to the receiver operating characteristic (ROC) curve analysis of the best discrimination point between TSH\/free T4\/LDL and MACE attack.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In participants receiving thyroxine with diabetes, patients with worse renal function, hypertension, history of diabetic microvascular complications, ESRD, CHD, heart failure, CVA, and diabetic foot infection had a higher risk of experiencing MACE, but peripheral artery disease (PAD) was not a significant risk of MACE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1721865","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:14:33Z","timestamp":1767935673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors and clinical implications of thyroxine replacement therapy on major adverse cardiovascular events in type 2 diabetes: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Chih-Wei","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pi-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-011-0189-x","article-title":"Cardiovascular disease risk factors and cognition in the elderly","volume":"5","author":"Leritz","year":"2011","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15655","article-title":"Peripheral artery disease as a risk factor for myocardial infarction","volume":"13","author":"Mejias","year":"2021","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5551\/jat.32755","article-title":"Thyroid hormone and vascular remodeling","volume":"23","author":"Ichiki","year":"2016","journal-title":"J Atheroscl thrombosis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/1874192401105010076","article-title":"Effects of thyroid dysfunction on lipid profile","volume":"5","author":"Rizos","year":"2011","journal-title":"Open Cardiovasc Med J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00030.2013","article-title":"Thyroid hormone regulation of metabolism","volume":"94","author":"Mullur","year":"2014","journal-title":"Physiol Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2012.01.012","article-title":"The effect of thyroid disorders on lipid levels and metabolism","volume":"96","author":"Duntas","year":"2012","journal-title":"Med Clinics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103631","article-title":"A correlation of clinical and hemodynamic studies in patients with hypothyroidism","volume":"37","author":"Graettinger","year":"1958","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020493","article-title":"Increased central arterial stiffness in hypothyroidism","volume":"87","author":"Obuobie","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.411","article-title":"Flow-mediated, endothelium-dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values","volume":"7","author":"Lekakis","year":"1997","journal-title":"Thyroid"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030039","article-title":"Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy","volume":"88","author":"Taddei","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1210\/er.2006-0043","article-title":"The clinical significance of subclinical thyroid dysfunction","volume":"29","author":"Biondi","year":"2008","journal-title":"Endocrine Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031669","article-title":"Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study","volume":"89","author":"Monzani","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01361","article-title":"Systemic thyroid hormone status during levothyroxine therapy in hypothyroidism: A systematic review and meta-analysis","volume":"103","author":"McAninch","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1640086","article-title":"Effect of levothyroxine on major adverse cardiovascular events in patients with hypothyroidism and cardiovascular disease","volume":"16","author":"Liu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1527271","article-title":"Research status of subclinical hypothyroidism promoting the development and progression of cardiovascular diseases","volume":"12","author":"Wang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf208","article-title":"Assessing the cardiovascular effects of levothyroxine use in an ageing United Kingdom population (ACEL-UK): cohort study","volume":"110","author":"Holley","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001505","article-title":"Assessment of causal association between thyroid function and lipid metabolism: a Mendelian randomization study","volume":"134","author":"Wang","year":"2021","journal-title":"Chin Med J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.08.015","article-title":"Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function","volume":"11","author":"Jung","year":"2017","journal-title":"J Clin lipidology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00511","article-title":"A renewed focus on the association between thyroid hormones and lipid metabolism","volume":"9","author":"Duntas","year":"2018","journal-title":"Front endocrinology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijcbr.2021.006","article-title":"Association between thyroid hormones & lipid profile in type 2 diabetes mellitus patients-A case control study in tertiary care hospital","volume":"8","author":"Pangajam","year":"2023","journal-title":"Int J Clin Biochem Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4236\/ojemd.2013.32017","article-title":"A comparative study of thyroid hormone and lipid status of patient with and without diabetes in adults","volume":"3","author":"Saha","year":"2013","journal-title":"Open J Endocrine Metab Diseases"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000360558","article-title":"Cardiovascular disease and thyroid function","volume":"43","author":"Faber","year":"2014","journal-title":"Front Horm Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2226","article-title":"Long-term outcome in levothyroxine treated patients with subclinical hypothyroidism and concomitant heart disease","volume":"101","author":"Andersen","year":"2016","journal-title":"J Of Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4184","article-title":"Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study","volume":"99","author":"Selmer","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13472","article-title":"Thyroid-stimulating hormone and risk of sudden cardiac death, total mortality and cardiovascular morbidity","volume":"88","author":"Langen","year":"2018","journal-title":"Clin endocrinology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e002407","DOI":"10.1136\/bmjdrc-2021-002407","article-title":"Type 2 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease","volume":"9","author":"Sprenger","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.045","article-title":"Thyroid hormones and cardiovascular function and diseases","volume":"71","author":"Razvi","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-015-0032-3","article-title":"Improvement of blood inflammatory marker levels in patients with hypothyroidism under levothyroxine treatment","volume":"15","author":"Marchiori","year":"2015","journal-title":"BMC Endocrine Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1408684","article-title":"Hypothyroidism and metabolic cardiovascular disease","volume":"15","author":"Patrizio","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e52512","DOI":"10.7759\/cureus.52512","article-title":"Hypothyroidism and cardiovascular disease: A review","volume":"16","author":"Z\u00fa\u00f1iga","year":"2024","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/j2020012","article-title":"Inflammation and peripheral arterial disease","volume":"2","author":"Signorelli","year":"2019","journal-title":"J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1013641","article-title":"Effect of levothyroxine replacement therapy in patients with subclinical hypothyroidism and chronic heart failure: A systematic review","volume":"13","author":"Triggiani","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13643-024-02548-7","article-title":"Cardiovascular and bone health outcomes in older people with subclinical hypothyroidism treated with levothyroxine: a systematic review and meta-analysis","volume":"13","author":"Holley","year":"2024","journal-title":"Syst Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0227","article-title":"Levothyroxine treatment of subclinical hypothyroidism and the risk of adverse cardiovascular events","volume":"34","author":"Yu","year":"2024","journal-title":"Thyroid"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1721865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:14:34Z","timestamp":1767935674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1721865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":34,"alternative-id":["10.3389\/fendo.2025.1721865"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1721865","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1721865"}}